Introduction

Assessing peptide cytotoxicity is a critical step in the preclinical development of peptide therapeutics and a fundamental requirement for in vitro research applications. Whether evaluating a novel antimicrobial peptide, a cell-penetrating peptide drug delivery system, or a peptide-conjugated nanoparticle, robust cytotoxicity data are essential for dose selection, safety assessment, and regulatory compliance. This tutorial provides step-by-step protocols for the four most common peptide cytotoxicity assays, with practical guidance on assay selection, protocol optimization, and data interpretation.

Assay 1: MTT Reduction Assay (Metabolic Activity)

The MTT assay measures mitochondrial reductase activity as a surrogate for viable cell number. Viable cells reduce yellow MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) to purple formazan crystals, which are solubilized in DMSO and quantified at 570 nm. Key protocol considerations: seed 5,000-10,000 cells/well in 96-well plates 24 hours before treatment; incubate peptides at 0.1-100 μM for 24-72 hours; add 10 μL MTT (5 mg/mL), incubate 4 hours; dissolve formazan in 100 μL DMSO; read absorbance at 570 nm with 630 nm reference.

Critical controls include: untreated cells (100% viability), 1% Triton X-100 (0% viability), DMSO vehicle control at ≤0.1%, and doxorubicin (10 μM) as a positive cytotoxic control. Peptide interference with the MTT reduction reaction, independent of cytotoxicity, can produce false positives. Orthogonal viability assessment using the LDH assay is recommended for peptides with known redox activity, particularly cysteine-rich sequences.

Assay 2: LDH Release Assay (Membrane Integrity)

The lactate dehydrogenase (LDH) release assay quantifies plasma membrane damage by measuring LDH enzyme activity in culture supernatant. LDH catalyzes the conversion of lactate to pyruvate with concomitant reduction of NAD+ to NADH, which reduces a tetrazolium salt to a colored formazan product. Unlike the MTT assay, LDH release does not require intracellular metabolism and is less susceptible to interference from metabolically active peptides.

Protocol: collect 50 μL supernatant, add 50 μL LDH reaction mixture, incubate 30 minutes at room temperature protected from light, stop reaction with 50 μL stop solution, read at 490 nm. Maximum LDH release control (100% cytotoxicity) uses cells lysed with 1% Triton X-100 for 45 minutes. Spontaneous LDH release from untreated cells (typically 5-15%) serves as the baseline.

Assay 3: Annexin V/PI Flow Cytometry (Apoptosis vs Necrosis)

Annexin V-FITC/propidium iodide (PI) dual staining distinguishes early apoptotic (Annexin V+/PI-), late apoptotic/necrotic (Annexin V+/PI+), and necrotic (Annexin V-/PI+) cell populations. Annexin V binds phosphatidylserine externalized to the outer plasma membrane leaflet during early apoptosis, while PI enters cells with compromised membrane integrity characteristic of late apoptosis and necrosis.

Protocol: harvest 1×10⁵ cells by trypsinization (avoid over-trypsinization which may generate false-positive Annexin V signal); wash twice with cold PBS; resuspend in 100 μL binding buffer; add 5 μL Annexin V-FITC and 5 μL PI; incubate 15 minutes at room temperature in the dark; add 400 μL binding buffer; analyze within 1 hour by flow cytometry. Compensation controls (unstained, Annexin V-only, PI-only) are essential for accurate quadrant gating.

Assay 4: 3D Spheroid Viability (Advanced)

Three-dimensional tumor spheroid models more accurately recapitulate in vivo peptide penetration barriers and tumor microenvironment conditions. Acid phosphatase (APH) and CellTiter-Glo 3D assays are preferred for spheroid viability quantification as they avoid the diffusion limitations that confound MTT assays in 3D culture. Spheroids are generated by seeding 1,000-5,000 cells/well in ultra-low attachment 96-well plates and cultured for 72 hours before peptide treatment for 72-96 hours.

Data Analysis and IC₅₀ Determination

Dose-response data are fitted to a four-parameter logistic equation using nonlinear regression: Y = Bottom + (Top-Bottom)/(1 + 10^((LogIC₅₀-X)×HillSlope)). IC₅₀ values should be reported with 95% confidence intervals and R² goodness-of-fit metrics. N≥3 independent biological replicates with 3 technical replicates each are the minimum standard for publication-quality peptide cytotoxicity data.

Conclusion

A systematic cytotoxicity assessment using complementary assays provides the most reliable evaluation of peptide safety in vitro. Combining metabolic (MTT), membrane integrity (LDH), and mechanistic (Annexin V/PI) endpoints yields comprehensive toxicity profiles that inform dose selection for subsequent in vivo efficacy and toxicology studies.